“Heading into 1Q25, we also believe BPMC could be seen as an attractive target for strategic partnerships, which could boost shares,” JP Morgan writes. With Ayvakit’s launch being a major focus for ...

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.